A Study of Single and Multiple Doses HRS9531 Tablets in Healthy Subjects

Phase 1 Completed 72 enrolled Fujian Shengdi Pharmaceutical Co., Ltd.

RandomizedParallel-groupTriple-blindTreatment

Summary

The study is being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple doses of HRS9531tablets in healthy subjects.

Timeline

Start: 2024-06-04
Primary completion: 2024-10-08
Completion: 2024-10-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HRS9531	Unknown	—	Oral

A Study of Single and Multiple Doses HRS9531 Tablets in Healthy Subjects

Summary

Timeline

Drugs

Indications